Suven Life Sciences Ltd has announced that two of their New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases were granted patents in Australia (2003-249582 & 2003-249583) and New Zealand (537770 & 537772) and these Patents are valid until 2022.

The granted claims of these patents include the class of selective 5-HT compounds discovered by the company and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like alzheimer's, attention deficient hyperactivity, huntington's, parkinson and schizophrenia.

The company thus far has filed 25 product patents under PCT out of which 10 has entered national phase. These are the first product patents granted to the company from its four years of drugs discovery efforts. The company has already filed its first Investigational New Drug (IND) application with DCGI to conduct the clinical phase - I study on their developmental candidate SUVN-502.

The company continue to work on G-Protein coupled receptor (GPCR) targets to discover and develop molecules focusing on CNS disorders with unmet medical need and high market potential, says Venkat Jasti, CEO of the company.

The company is a Hyderabad based Life Science company, a Collaborative Research Partner (CRP) since 2006 in Drug Discovery and Development Support Services (DDDSS) since 2005. The company has been involved in development of path breaking technologies for global Pharma companies for more then a decade.

A focused provider of DDDSS for development of New Chemical Entities to life sciences companies. The company's commitment to protection of intellectual property, maximization of return on R&D investments for collaborative research partner, ability to offer full spectrum of service from discovery to market launch and provide technologies and expertise in different therapeutic areas. The company has R&D strength of more than 255 professional with the state of the art infrastructure for Drug Discovery and development activities and the front and project management services from New Jersey, USA.